Skip to content

Biodesix, Inc. BDSX Debt-to-equity

Debt-to-equity at other companies

NeoGenomics logo
NeoGenomicsNEO
0.1×0.0×
Veracyte logo
VeracyteVCYT
0.0×
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-0.2×
Personalis, Inc. logo
Personalis, Inc.PSNL
0.2×0.0×
Guardant Health logo
Guardant HealthGH
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
0.2×0.0×

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Current ratio2.8×+0.6×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s debt-to-equity?
Biodesix, Inc. (BDSX) reported debt-to-equity of 7.8× in Q1 2026.
How has Biodesix, Inc.'s debt-to-equity changed year-over-year?
Biodesix, Inc.'s debt-to-equity increased by 39.3% year-over-year, from 5.6× to 7.8×.
What is the long-term trend for Biodesix, Inc.'s debt-to-equity?
Over 4 years (2020 to 2024), Biodesix, Inc.'s debt-to-equity has grown at a 66.4% compound annual growth rate (CAGR), from 0.4× to 3×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.